Different phenotypes of lattice corneal dystrophy type I in patients with 417C>T (R124C) and 1762A>G (H572R) mutations in TGFBI (BIGH3).
OBJECTIVE
To describe clinical data and to characterize mutations in the transforming growth factor beta-induced (TGFBI) gene in patients from three unrelated Chilean families with lattice corneal dystrophy type I (LCDI).


METHODS
Snellen acuity tests, anterior segment slit lamp examinations, dilated fundus evaluations, and tonometry were performed for seven patients--five females and two males belonging to three unrelated families--affected with lattice corneal dystrophy Type I. Genomic DNA was also extracted from peripheral leukocytes from the seven patients and four healthy relatives. The 417C>T mutation (R124C) was screened using PCR-RFLP for the seven patients and four healthy relatives. Exons 11, 12, 13, and 14 were sequenced in one patient not carrying the mutation in codon 124. Comparison of phenotype to genotype was performed.


RESULTS
The seven patients studied exhibited LCDI in both eyes, most of which were symmetric. Affected individuals demonstrated progression from central subepithelial needlelike deposits and polymorphic anterior stromal opacities. The age at onset of symptoms varied between six to 15 years old in Family One; the patient in Family Two was five years old and the patient in Family Three was 21 years old. Visual acuity varied from 1.0 to 0.05. Two patients, aged 50 and 45 years, underwent penetrating keratoplasty in both eyes, and two patients, aged 47 and 24 years, underwent penetrating keratoplasty in one eye. The only patient in Family Three exhibited a somewhat distinct phenotype, with yellowish discoloration in the anterior stroma and fewer, but thicker lattice lines than the patients in Families One and Two. Screening for the mutation C>T at the nucleotide position 417 (R124C) in exon 4 in the three families revealed the heterozygous R124C mutation in Families One and Two. In Family Two, the mutation was a de novo mutation, as neither parent was a carrier. Screening by sequencing analysis for mutation in exons 11, 12, 13, and 14 in the affected patient in Family Three revealed a heterozygous A1762G mutation (H572R) in exon 13.


CONCLUSIONS
This is the second report of the 417C>T mutation and the first report of 1762 A>G mutation (H572R) in Chilean patients. The H572R mutation identified is associated with a distinct lattice corneal dystrophy type I phenotype.
Romero
Pablo
P
Depto. de Oftalmología, Hospital Clínico José Joaquín Aguirre, Universidad de Chile, Santiago, Chile.
Moraga
Mauricio
M
Herrera
Luisa
L
D000328:Adult; D000369:Aged, 80 and over; D001483:Base Sequence; D003315:Cornea / Q000473:pathology; D003317:Corneal Dystrophies, Hereditary / Q000235:genetics* / Q000473:pathology*; D004252:DNA Mutational Analysis; D005091:Exons / Q000235:genetics; D016326:Extracellular Matrix Proteins / Q000235:genetics*; D005190:Family; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009154:Mutation / Q000235:genetics*; D010375:Pedigree; D010641:Phenotype; D012150:Polymorphism, Restriction Fragment Length; D016212:Transforming Growth Factor beta / Q000235:genetics*; D055815:Young Adult; D000099222:betaIG-H3 Protein
D016326:Extracellular Matrix Proteins; D016212:Transforming Growth Factor beta; D000099222:betaIG-H3 Protein
Nat Genet. 1994 Jan;6(1):47-51
8136834
Mol Vis. 2008 May 07;14:829-35
18470323
Eye (Lond). 2007 May;21(5):587-90
16440005
Am J Ophthalmol. 1998 Apr;125(4):547-9
9559741
Jpn J Ophthalmol. 2003 Jan-Feb;47(1):13-7
12586172
J Biol Chem. 1996 Jan 19;271(3):1314-21
8576118
Am J Pathol. 1967 Mar;50(3):371-99
4163628
J Biol Chem. 2009 Jul 17;284(29):19580-91
19478074
Mol Vis. 2003 Sep 11;9:440-8
14502125
Invest Ophthalmol Vis Sci. 2002 Apr;43(4):949-54
11923233
Am J Pathol. 1998 Mar;152(3):743-8
9502416
Br J Ophthalmol. 2003 Jun;87(6):686-9
12770961
Biochim Biophys Acta. 1999 Aug 12;1451(1):196-205
10446401
Hum Mutat. 1999;14(2):126-32
10425035
Am J Ophthalmol. 2004 Mar;137(3):586-8
15013897
Ophthalmologica. 2004 Nov-Dec;218(6):411-4
15564760
Arch Ophthalmol. 1999 Jan;117(1):67-75
9930162
Cornea. 2000 Nov;19(6):842-5
11095060
Mol Vis. 2006 May 10;12:461-6
16710170
Am J Ophthalmol. 1999 Dec;128(6):747-54
10612512
Ophthalmology. 2001 Apr;108(4):818-23
11297504
Nat Genet. 1997 Mar;15(3):247-51
9054935
J Cell Biochem. 2000 Mar;77(2):169-78
10723084
J Invest Dermatol. 1995 May;104(5):844-9
7738366
Curr Eye Res. 2000 Nov;21(5):891-6
11262611
Structure. 2003 Feb;11(2):197-203
12575939
Jpn J Ophthalmol. 2006 Sep-Oct;50(5):403-408
17013691
Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2213-9
10476785
Arch Ophthalmol. 2004 Aug;122(8):1224-7
15302666
Cell. 1988 May 20;53(4):577-87
3370670
Arch Ophthalmol. 1999 Jan;117(1):90-3
9930165
Nucleic Acids Res. 1991 Oct 11;19(19):5444
1681511
Invest Ophthalmol Vis Sci. 2000 May;41(6):1302-8
10798644
Am J Hum Genet. 1998 Feb;62(2):320-4
9463327
J Cell Physiol. 1994 Sep;160(3):511-21
8077289
DNA Cell Biol. 1992 Sep;11(7):511-22
1388724
Hum Mutat. 2006 Jul;27(7):615-25
16683255